Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
AEON Biopharma ( (AEON) ) just unveiled an update.
AEON Biopharma announced the pricing of a $20 million underwritten public offering to support the development of ABP-450 as a biosimilar to BOTOX® for therapeutic uses. The funds raised are expected to sustain the company’s operations through 2025, facilitating necessary studies under the 351(k) regulatory pathway and supporting a planned meeting to discuss study outcomes and future steps.
More about AEON Biopharma
AEON Biopharma is a clinical-stage biopharmaceutical company focusing on developing a botulinum toxin complex, ABP-450, for therapeutic uses, particularly in the neurosciences market. The company holds exclusive development and distribution rights in multiple regions, including the U.S., Canada, and Europe, and has an experienced management team in biopharmaceutical and botulinum toxin development.
YTD Price Performance: 3.64%
Average Trading Volume: 200,562
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $22.74M
See more data about AEON stock on TipRanks’ Stock Analysis page.
